Your browser is no longer supported. Please, upgrade your browser.
Settings
TCON [NASD]
TRACON Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.72 Insider Own0.10% Shs Outstand15.48M Perf Week-10.05%
Market Cap67.01M Forward P/E- EPS next Y-1.25 Insider Trans250.71% Shs Float10.04M Perf Month-50.65%
Income-17.80M PEG- EPS next Q-0.31 Inst Own50.20% Short Float6.92% Perf Quarter-52.91%
Sales- P/S- EPS this Y75.00% Inst Trans0.23% Short Ratio2.56 Perf Half Y-64.84%
Book/sh1.32 P/B2.58 EPS next Y0.80% ROA-63.20% Target Price- Perf Year102.38%
Cash/sh1.54 P/C2.20 EPS next 5Y- ROE-111.50% 52W Range1.55 - 12.20 Perf YTD-70.94%
Dividend- P/FCF- EPS past 5Y38.90% ROI- 52W High-71.23% Beta1.83
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low126.45% ATR0.41
Employees18 Current Ratio3.00 Sales Q/Q- Oper. Margin- RSI (14)26.02 Volatility6.82% 8.45%
OptionableYes Debt/Eq0.17 EPS Q/Q57.90% Profit Margin- Rel Volume1.02 Prev Close3.40
ShortableYes LT Debt/Eq0.03 EarningsAug 11 AMC Payout- Avg Volume271.00K Price3.51
Recom1.90 SMA20-26.22% SMA50-39.20% SMA200-54.03% Volume58,509 Change3.24%
Apr-16-21Upgrade BTIG Research Neutral → Buy $14
Feb-10-21Initiated Maxim Group Buy $24
Dec-23-19Reiterated H.C. Wainwright Buy $15 → $18
Mar-01-19Reiterated Needham Buy $7
Jun-13-17Reiterated Stifel Buy $14 → $6
Dec-21-16Initiated Jefferies Buy $10
Feb-01-16Resumed Oppenheimer Outperform
Jul-29-15Initiated ROTH Capital Buy $18
Mar-02-15Reiterated Stifel Buy $16 → $20
Mar-02-15Reiterated Oppenheimer Outperform $22 → $26
Feb-24-15Initiated Stifel Buy $16
Feb-24-15Initiated Oppenheimer Outperform $22
Aug-03-21 08:05AM  
Jul-28-21 08:05AM  
Jul-21-21 10:30PM  
05:27PM  
Jul-20-21 08:05AM  
Jun-30-21 08:05AM  
Jun-29-21 08:05AM  
Jun-28-21 01:04PM  
Jun-18-21 10:08AM  
Jun-04-21 09:01AM  
Jun-01-21 08:05AM  
May-25-21 08:05AM  
May-20-21 08:05AM  
May-05-21 04:03PM  
02:45PM  
08:25AM  
May-03-21 08:05AM  
Apr-28-21 08:05AM  
Apr-26-21 08:00AM  
Mar-23-21 08:05AM  
Mar-09-21 08:05AM  
Mar-08-21 08:05AM  
Mar-02-21 08:05AM  
Feb-25-21 04:03PM  
02:30PM  
Feb-18-21 08:05AM  
Jan-28-21 11:40AM  
Jan-19-21 08:05AM  
Jan-06-21 08:05AM  
Dec-30-20 08:05AM  
Dec-29-20 08:05AM  
Dec-22-20 08:05AM  
Dec-10-20 08:05AM  
Dec-04-20 08:29AM  
Dec-03-20 09:14AM  
Nov-30-20 04:17PM  
Nov-23-20 08:05AM  
Nov-16-20 09:45AM  
Nov-10-20 04:03PM  
02:45PM  
Nov-03-20 08:05AM  
Oct-26-20 08:05AM  
Sep-25-20 11:29AM  
Sep-21-20 08:05AM  
Sep-10-20 08:05AM  
Sep-09-20 11:51AM  
Sep-03-20 08:05AM  
Aug-31-20 08:05AM  
Aug-27-20 08:05AM  
Aug-25-20 11:49AM  
Aug-24-20 11:59AM  
Aug-17-20 11:08AM  
08:38AM  
08:05AM  
Aug-05-20 04:05PM  
Aug-03-20 08:05AM  
Jul-29-20 04:05PM  
Jul-16-20 08:15AM  
Jul-13-20 08:15AM  
Jun-22-20 02:19PM  
Jun-11-20 10:56PM  
Jun-05-20 02:48PM  
Jun-01-20 08:05AM  
May-29-20 08:20AM  
May-14-20 08:32AM  
May-13-20 04:04PM  
May-11-20 08:15AM  
May-06-20 04:05PM  
Apr-24-20 08:15AM  
Apr-14-20 08:15AM  
Apr-06-20 08:15AM  
Mar-19-20 08:15AM  
Mar-18-20 03:29AM  
Mar-16-20 08:15AM  
Mar-09-20 07:40PM  
Feb-28-20 07:28AM  
Feb-27-20 04:03PM  
Feb-20-20 06:00PM  
Feb-07-20 08:05AM  
Jan-20-20 01:14PM  
Dec-22-19 05:10PM  
Dec-20-19 08:58AM  
07:00AM  
Nov-21-19 09:37PM  
Nov-08-19 08:05AM  
Nov-05-19 04:05PM  
Oct-29-19 04:15PM  
Oct-21-19 08:05AM  
Oct-07-19 12:40PM  
Sep-03-19 08:05AM  
Aug-29-19 08:05AM  
Aug-28-19 08:05AM  
Aug-07-19 04:02PM  
08:05AM  
Aug-01-19 11:33AM  
08:05AM  
Jul-31-19 04:05PM  
Jul-29-19 08:05AM  
Jul-02-19 08:05AM  
Jun-27-19 11:40AM  
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PELLETIER SAUNDRA LDirectorJul 26Buy3.826,54525,00212,045Jul 27 06:00 AM
LARUE WILLIAM RDirectorJul 26Buy3.826,54525,0027,883Jul 27 06:00 AM
Brown Scott B.Chief Financial OfficerMar 08Buy8.301,0008,2963,128Mar 09 06:00 AM
THEUER CHARLESPresident and CEOJan 27Buy8.9811,00098,771201,232Jan 28 06:00 AM
Ikarian Capital, LLCMember of 10% GroupDec 30Buy9.61520,2914,999,9972,716,840Dec 30 06:24 PM
THEUER CHARLESPresident and CEODec 29Buy9.981,0009,980190,232Dec 30 06:00 AM
WIGGINS MARK CChief Business OfficerDec 29Buy10.571,00010,57013,700Dec 30 06:00 AM
Opaleye Management Inc.10% OwnerDec 22Buy8.06496,2773,999,9932,293,371Dec 28 09:53 AM
Ikarian Capital, LLCMember of 10% GroupNov 11Buy7.535,00037,6292,196,549Nov 12 06:18 PM
Ikarian Capital, LLCMember of 10% GroupOct 30Buy4.6421,30098,9072,191,549Nov 12 06:18 PM
Ikarian Capital, LLCMember of 10% GroupOct 29Buy4.777,70036,7342,170,249Nov 12 06:18 PM
THEUER CHARLESPresident and CEOOct 21Buy4.382,0008,769189,232Oct 23 06:00 AM
Opaleye Management Inc.10% OwnerOct 21Buy4.408,65638,0601,797,094Oct 23 09:30 PM
Opaleye Management Inc.10% OwnerSep 24Buy4.4421,53495,6481,785,438Sep 25 09:30 PM
Opaleye Management Inc.10% OwnerSep 23Buy4.8357,200276,4481,764,438Sep 25 09:30 PM
THEUER CHARLESPresident and CEOSep 23Buy4.725,00023,599186,882Sep 25 06:00 AM
Ikarian Capital, LLCMember of 10% GroupSep 11Buy3.9378,201307,0172,162,549Sep 15 09:19 PM
WIGGINS MARK CChief Business OfficerSep 10Buy4.147,00028,95312,350Sep 14 01:49 PM
Opaleye Management Inc.10% OwnerSep 09Buy3.4747,500164,7731,709,438Sep 09 06:15 PM
Ikarian Capital, LLCMember of 10% GroupSep 09Buy3.4979,415277,4602,084,348Sep 15 09:19 PM
Ikarian Capital, LLCMember of 10% GroupSep 08Buy2.9013,24438,4082,004,933Sep 15 09:19 PM
Ikarian Capital, LLCMember of 10% GroupSep 04Buy2.87151,611434,5021,991,689Sep 15 09:19 PM
Opaleye Management Inc.10% OwnerSep 04Buy2.889,05826,1301,664,438Sep 09 06:15 PM
THEUER CHARLESPresident and CEOSep 04Buy2.5810,00025,750181,882Sep 09 06:00 AM
Opaleye Management Inc.10% OwnerSep 02Buy2.35119,800282,0571,655,946Sep 03 05:15 PM
Opaleye Management Inc.10% OwnerSep 01Buy2.0440,00081,7681,540,946Sep 03 05:15 PM
Opaleye Management Inc.10% OwnerAug 31Buy1.76302,150530,4551,502,346Aug 31 09:36 PM
Opaleye Management Inc.10% OwnerAug 28Buy1.7860,000106,974210,000Aug 31 09:36 PM
Opaleye Management Inc.10% OwnerAug 27Buy1.71183,354312,9491,206,196Aug 31 09:36 PM
THEUER CHARLESPresident and CEOAug 21Buy1.565,3258,307171,882Aug 25 06:00 AM
THEUER CHARLESPresident and CEOAug 20Buy1.5830,00047,400166,557Aug 24 06:06 AM
THEUER CHARLESPresident and CEOAug 18Buy1.6344,74372,851136,557Aug 18 08:28 PM
THEUER CHARLESPresident and CEOAug 14Buy1.7010017091,814Aug 18 08:28 PM
THEUER CHARLESPresident and CEOAug 13Buy1.655,0008,25091,714Aug 14 08:17 PM
THEUER CHARLESPresident and CEOAug 12Buy1.7515,00026,25086,714Aug 14 08:17 PM